ADVIK LABORATORIES LTD.

Advik Laboratories Ltd has announced the closure of its trading window for directors, promoters, KMPs, designated employees, and their immediate relatives. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's code of conduct. The window will remain shut from July 1, 2026, until 48 hours after the declaration of the company's unaudited financial results for the quarter ending June 30, 2026. The date for the board meeting to approve these results will be communicated separately.

MPS Pharmaa's Board of Directors approved the standalone audited financial results for the quarter and financial year ended March 31, 2026. The board also re-appointed M/s Sanghi & Co., Chartered Accountants, as the Internal Auditor for FY 2026-27. The company reported a total income of ₹3.56 Lacs for Q4 FY26 and ₹6.3 Lacs for FY26, with a basic EPS of (₹0.19) for Q4 FY26 and (₹0.53) for FY26. The audit report included qualifications regarding investment valuation and stalled capital work in progress. The company is actively working to restart business operations and address outstanding Annual Listing Fees, which led to BSE suspending trading of its scrip.

MPS Pharmaa Limited's Board approved its standalone audited financial results for the quarter and financial year ended March 31, 2026. For FY26, the company reported a total comprehensive loss of ₹101.22 Lacs, widening from ₹88.81 Lacs in FY25, with an EPS of (0.53). The auditors issued a modified opinion, citing inability to verify investments worth ₹53.80 Lacs and concerns over stalled Capital Work in Progress of ₹2.41 Crore. The company explained that investment share certificates were misplaced and construction was temporarily suspended. M/s Sanghi & Co. was re-appointed as Internal Auditor. The company's drug manufacturing license renewal is pending, and it is actively seeking to restart business operations. Trading of its shares on BSE remains suspended due to unpaid Annual Listing Fees since FY21-22, with limited trading allowed on a trade-for-trade basis.

Advik Laboratories Ltd has scheduled a Board of Directors meeting on May 28, 2026, to consider and approve the audited financial results for the quarter and financial year ended March 31, 2026. The board will also consider the appointment of M/s Sanghi & Co. as the Internal Auditor for FY 2026-27. The trading window remains closed until May 30, 2026.

MPS Pharmaa Limited, formerly Advik Laboratories Limited, has confirmed that it does not meet the criteria to be classified as a "Large Corporate" (LC) as of March 31, 2026. This declaration is made in accordance with SEBI Circular No. SEBI/HO/DDHS/P/CIR/2021/613 dated August 10, 2021, read with SEBI/HO/DDHS/DDHS-RACPOD1/P/CIR/2023/172 dated October 19, 2023, and SEBI/HO/DDHS CIR/P/2018/144 dated November 26, 2018. Consequently, the company is not subject to the specific disclosure and compliance requirements for Large Corporates concerning fund-raising through the issuance of debt securities.

Advik Laboratories Ltd has submitted its statement of investor complaints for the quarter ended March 31, 2026, in compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company reported zero investor complaints pending at the beginning of the quarter, zero complaints received during the quarter, zero complaints disposed of, and zero complaints remaining unresolved at the end of the quarter.

Advik Laboratories Ltd has reported that there were no investor complaints for the quarter and year ended March 31, 2026. As per Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company confirmed that zero complaints were pending at the beginning of the quarter, zero were received, zero were disposed of, and zero remained unresolved at the end of the quarter. This indicates effective investor grievance management.

Advik Laboratories Ltd, now known as MPS Pharmaa Limited, has announced the closure of its trading window for all directors, promoters, KMPs, designated persons/employees, and their immediate relatives. The closure will be in effect from Wednesday, 01st April, 2026 until 48 hours after the quarter and year ending 31st March, 2026. The decision comes in accordance with the SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's code of conduct for prevention of Insider Trading.

Advik Laboratories Ltd., formerly known as MPS Pharmaa Limited, held a separate meeting of its Independent Directors on 25th March 2026. The meeting was conducted at the corporate office in New Delhi. The Independent Directors reviewed the performance of Non-Independent Directors and the Board as a whole, and assessed the quality, quantity, and timeliness of flow of information between the management and the Board. The meeting concluded at 12:50 PM.

Advik Laboratories Ltd, a renowned company, has announced a separate meeting of its Independent Directors. The meeting is scheduled to be held on Wednesday, 25th March, 2026, at 11:00 A.M., at the corporate office of the company in New Delhi. The agenda of the meeting includes reviewing the performance of non-Independent Directors and the Board as a whole, and assessing the quality, quantity, and timeliness of flow of information between the company management and the Board.